Durata Therapeutics, established in 2009 in Morristown, New Jersey, is a clinical development stage pharmaceutical company which focuses on the treatment of infectious diseases. The company acquired dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer in December 2009. Durata has initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections. In 2012, the company moved its global headquarters from Morristown to Chicago in a deal with $2 million in tax credits. In October 2014 Durata was acquired by Actavis for about $675 million.